利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.012 秒)

    METHOD FOR DETECTING GRANULAR SUBSTANCE BY IMMUNOCHROMATOGRAPHY METHOD, AND KIT FOR SAME
    1.
    发明公开
    METHOD FOR DETECTING GRANULAR SUBSTANCE BY IMMUNOCHROMATOGRAPHY METHOD, AND KIT FOR SAME 审中-公开

    公开(公告)号：EP4257979A1

    公开(公告)日：2023-10-11

    申请号：EP21903387.5

    申请日：2021-12-07

    申请人： Dai Nippon Toryo Co., Ltd. ,  Shimadzu Corporation

    发明人： MIYAZAWA ,Yuta ,  FUJIMOTO, Hirotaka ,  WATANABE, Makoto ,  SATO, Taka-Aki

    IPC分类号： G01N33/543

    摘要： An object of the present invention is to provide a method for detecting particulate substances with a high degree of sensitivity, while suppressing the generation of non-specific signals.
    According to the present invention, the generation of non-specific signals in the background can be suppressed by blocking a membrane of a test strip which is used for immunochromatography with a blocking composition comprising a polymer-based blocking agent having, in its side chain, a substituent represented by the following formula:

    (wherein R 1 , R 2 , and R 3 are each independently a hydrogen atom, a C 1-6 alkyl group, or a C 1-6 hydroxyalkyl group; and n is an integer of 1 to 4), and having a weight average molecular weight (Mw) of 1 × 10 3 to 1 × 10 7 .

    METHOD FOR EVALUATING MYOCARDIAL ISCHEMIC STATE USING BLOOD SAMPLE
    3.
    发明公开
    METHOD FOR EVALUATING MYOCARDIAL ISCHEMIC STATE USING BLOOD SAMPLE 有权
    VERFAHREN ZUR BEWERTUNG EINESISCHÄMISCHENMYOKARDZUSTANDS MITTELS BLUTPROBE

    公开(公告)号：EP2322935A1

    公开(公告)日：2011-05-18

    申请号：EP08809519.5

    申请日：2008-08-28

    申请人： Shimadzu Corporation ,  The University of Tokyo

    发明人： FUJIMOTO, Hirotaka ,  SUZUKI, Toru

    IPC分类号： G01N33/68 ,  G01N27/62

    CPC分类号： G01N33/6893 ,  C07K16/26 ,  C07K2317/34 ,  G01N33/543 ,  G01N33/74 ,  G01N2333/58 ,  G01N2800/32

    摘要： The present invention provides a method and an index capable of less-invasively determining myocardial ischemia such as ischemic heart disease or restenosis after percutaneous coronary intervention. The present invention also provides an index that allows the cardiovascular disease other than heart failure to be determined even from a blood sample showing a BNP value from which the cardiovascular disease other than heart failure cannot be determined by a conventional method. A method for determining myocardial ischemia comprising subjecting a blood sample which is derived from a test subject and which contains a BNP molecular group containing at least two selected from the group consisting of BNP 1-32 molecule, BNP 3-32 molecule, BNP 4-32 molecule, BNP 5-32 molecule, and a molecule having a mass number larger than that of BNP 5-32 molecule by 16 Da to a detection process capable of distinguishing and quantifying the individual BNP molecules different in mass number to detect the BNP molecular group, wherein myocardial ischemia in the test subject is determined using, as an index, a ratio between a detected intensity of at least one molecule selected from the BNP molecular group and a detected intensity of at least one other molecule selected from the BNP molecular group.

    摘要翻译： 本发明提供一种能够较少侵袭性地测定经皮冠状动脉介入治疗后缺血性心脏病或再狭窄等心肌缺血的方法和指标。 本发明还提供了即使从显示BNP值的血液样品中也可以确定心力衰竭以外的心血管疾病的指标，除了心力衰竭以外的心血管疾病不能通过常规方法来确定。 一种用于测定心肌缺血的方法，其特征在于，对来自受检对象的含有BNP分子组的BNP 1-32分子，BNP 3-32分子，BNP 4- 32分子，BNP 5-32分子，以及质量数大于BNP 5-32分子的质量数的分子16Da以上的检测方法，其能够区分和定量质量数不同的各BNP分子，以检测BNP分子 组，其中使用选自BNP分子基团的至少一种分子的检测强度和选自BNP分子组的至少一种其他分子的检测强度之间的比率作为指标来确定测试对象中的心肌缺血 。